Wells T N, Proudfoot A E
Serono Pharmaceutical Research Institute, Geneva, Switzerland.
Inflamm Res. 1999 Jul;48(7):353-62. doi: 10.1007/s000110050472.
The trafficking and homing of leukocytes in normal homeostasis and in disease is under the control of a variety of cytokine and lipid mediators. One family of small cytokines particularly involved in inflammation which has been identified is the chemokine family. Their action is mediated by a large superfamily of seven transmembrane spanning G-protein coupled receptors. One of the hopes in this field has been there may be selectivity in terms of which cells are recruited to sites of inflammation by virtue of their chemokine receptor expression pattern. This means that it may be possible to find antagonists of chemokine receptors that can selectively down regulate certain cell type recruitment, without provoking a generalized immunosuppression. In this review, we discuss the current state of understanding of the chemokine receptor field. The therapeutic potential of this field can be judged from recent data on the use of protein chemokine antagonists in allergic disease. The data so far obtained in animal studies point to the potential clinical uses of this emerging class of therapeutic agents.
在正常稳态和疾病状态下，白细胞的运输和归巢受多种细胞因子和脂质介质的控制。已确定的一个特别参与炎症反应的小细胞因子家族是趋化因子家族。它们的作用由一个由七个跨膜的G蛋白偶联受体组成的大型超家族介导。该领域的一个希望是，根据趋化因子受体的表达模式，在将哪些细胞招募到炎症部位方面可能存在选择性。这意味着有可能找到趋化因子受体拮抗剂，它们可以选择性地下调某些细胞类型的募集，而不会引发全身性免疫抑制。在这篇综述中，我们讨论了趋化因子受体领域的当前理解状态。该领域的治疗潜力可以从最近关于在过敏性疾病中使用蛋白质趋化因子拮抗剂的数据中判断。到目前为止在动物研究中获得的数据表明了这类新兴治疗药物的潜在临床用途。
